| Secondary |
| Atrial Fibrillation |
20.6% |
| Hiv Infection |
17.5% |
| Drug Use For Unknown Indication |
11.9% |
| Product Used For Unknown Indication |
9.1% |
| Pulmonary Embolism |
4.2% |
| Contusion |
3.5% |
| Hyperlipidaemia |
3.5% |
| Breast Cancer |
3.1% |
| Hypertension |
3.1% |
| Pain |
3.1% |
| Hypercholesterolaemia |
2.8% |
| Rheumatoid Arthritis |
2.8% |
| Anticoagulant Therapy |
2.4% |
| Prophylaxis |
2.4% |
| Percutaneous Coronary Intervention |
2.1% |
| Colon Cancer Metastatic |
1.7% |
| Thrombosis Prophylaxis |
1.7% |
| Cerebral Infarction |
1.4% |
| Diabetes Mellitus |
1.4% |
| Gastric Disorder |
1.4% |
|
| International Normalised Ratio Increased |
19.6% |
| Drug Interaction |
10.7% |
| Skin Ulcer |
8.9% |
| Subdural Haematoma |
8.9% |
| Nausea |
5.4% |
| Neutropenia |
5.4% |
| Cerebral Haemorrhage |
3.6% |
| Coagulation Factor Deficiency |
3.6% |
| Myocardial Infarction |
3.6% |
| Prothrombin Time Prolonged |
3.6% |
| Pulmonary Embolism |
3.6% |
| Pyrexia |
3.6% |
| Syncope |
3.6% |
| Wound |
3.6% |
| Wrong Technique In Drug Usage Process |
3.6% |
| Cardiac Arrest |
1.8% |
| Coagulation Factor Viii Level Decreased |
1.8% |
| Death |
1.8% |
| Enterocolitis Haemorrhagic |
1.8% |
| Extradural Haematoma |
1.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
19.5% |
| Drug Use For Unknown Indication |
10.7% |
| Hypertension |
9.7% |
| Atrial Fibrillation |
8.5% |
| Rheumatoid Arthritis |
6.7% |
| Cardiac Disorder |
5.7% |
| Cardiac Failure |
5.3% |
| Anticoagulant Therapy |
5.1% |
| Pain |
3.8% |
| Diabetes Mellitus |
3.6% |
| Prophylaxis |
3.2% |
| Osteoporosis |
2.9% |
| Arrhythmia |
2.5% |
| Parkinson's Disease |
2.2% |
| Asthma |
1.9% |
| Systemic Lupus Erythematosus |
1.8% |
| Blood Cholesterol |
1.8% |
| Blood Pressure |
1.7% |
| Cardiac Failure Chronic |
1.7% |
| Chronic Obstructive Pulmonary Disease |
1.7% |
|
| Vomiting |
13.8% |
| Urinary Tract Infection |
8.0% |
| Weight Decreased |
8.0% |
| Pruritus |
5.9% |
| Urticaria |
5.9% |
| Liver Injury |
5.3% |
| Thrombosis |
5.3% |
| International Normalised Ratio Increased |
4.3% |
| Nausea |
4.3% |
| Renal Failure |
4.3% |
| Death |
3.7% |
| Hallucination, Visual |
3.7% |
| Pain In Extremity |
3.7% |
| Pneumonia |
3.7% |
| Pulmonary Embolism |
3.7% |
| Wheezing |
3.7% |
| Nephrogenic Systemic Fibrosis |
3.2% |
| Oedema Peripheral |
3.2% |
| Sepsis |
3.2% |
| Surgery |
3.2% |
|
| Interacting |
| Drug Use For Unknown Indication |
24.3% |
| Atrial Fibrillation |
9.4% |
| Aortic Valve Replacement |
6.9% |
| Pain |
5.9% |
| Hypertension |
5.0% |
| Product Used For Unknown Indication |
5.0% |
| Rheumatoid Arthritis |
5.0% |
| Pneumonia |
4.5% |
| Urinary Tract Infection |
4.5% |
| Arthritis |
4.0% |
| Asthma |
4.0% |
| Fungal Infection |
3.5% |
| Anticoagulant Therapy |
3.0% |
| Epilepsy |
3.0% |
| Oral Candidiasis |
2.5% |
| Antiphospholipid Syndrome |
2.0% |
| Back Pain |
2.0% |
| Multiple Sclerosis |
2.0% |
| Procedural Pain |
2.0% |
| Systemic Lupus Erythematosus |
2.0% |
|
| International Normalised Ratio Increased |
33.9% |
| International Normalised Ratio Fluctuation |
13.6% |
| Drug Interaction |
5.1% |
| Haemorrhage Urinary Tract |
5.1% |
| Pulmonary Embolism |
5.1% |
| Haematuria |
3.4% |
| Melaena |
3.4% |
| Oedema Peripheral |
3.4% |
| Off Label Use |
3.4% |
| Prothrombin Time Shortened |
3.4% |
| Thrombosis |
3.4% |
| Urinary Bladder Haemorrhage |
3.4% |
| Epistaxis |
1.7% |
| Gastrointestinal Haemorrhage |
1.7% |
| Haematoma |
1.7% |
| Haemorrhage |
1.7% |
| Headache |
1.7% |
| International Normalised Ratio Decreased |
1.7% |
| Myocardial Infarction |
1.7% |
| Nystagmus |
1.7% |
|
